Abstract:Fluoroquinolones(FQs)are one of the commonest antibiotic groups that have been used for the treatment of bacterial infection. Enrofloxacin(EF) belongs to this group and has been increasingly used in veterinary medicine . A simple and reliable analytical method for this drug is required. The current determination by high performance liquid chromatography (HPLC) is sensitive but labor-intensive. Immunoassay methods have been successfully developed to rapidly screen EF residues. The synthesis and characteristics of complete antigens of EF were experimented. The results of this study indicated that the antibodies against EF may be used as the basis for an immunoassay to rapidly screen samples for the presence of FQs in tissues or body fluids. EF is a small molecule (MW1000) that must be conjugated to a carrier to elicit an immune response. Proteins are commonly used carriers, such as bovine serum albumin (BSA), ovalbumin (OVA), keyhole limpet hemocyanin (KLH) and Albumin Human (HSA). Using the free carboxylic acid on EF, it could be linked to protein carriers through the amide linkage. BSA and OVA were used as protein carriers to synthesize EF complete antigens respectively by both carbodiimide method and active ester method, which were then immunized to BALB/C rats. KLH was coupled to EF by carbodiimide method , the conjugation was used as coating antigen. The effects of coupling between haptens and carriers were investigated by UV spectrum, anti-serum, etc. The UV spectrum showed that the major absorbances of EF were in 208 nm, 271 nm and 334 nm, while protein had its major absorbances at 229 nm and 278 nm ; the EF-protein conjugates had a significant peak at 330-335 nm which were the main characteristic of EF but could not be seen in protein, so it could be concluded that the linkage between EF and protein were successfully set up. An indirect enzyme linked immunosorbant assay (ELISA ) was used to determine the titers of the antiserum, the titers of all the resultant polyclonal antibodies could reach 1∶50000. In ELISA procedure, the optimal dilution of coating antigen was determined by the checkerboard test and the optimum condition selected was coating antigen concentration in 10 μg·mL~ -1 and secondary antibody diluted 1∶10000. The hapten-protein ratio was calculated by formula at the range of 1-6. It used to believe that the amount of haptens coupled to the protein should be as much as possible. But in theory, the carrier protein linked even to one hapten may be enough to produce specific antibody, and in fact many researchers have proved that in some cases overabundance of the haptens with the carrier cannot result in desired responses, because it may prevent the protein from being present at the surface of immunoglobulins on B cells, and then interfere with the immune reaction. The results showed that the UV spectrum of protein-EF could coincide with the results of enzyme immunoassay of antiserums, so it could be used to indicate the characteristics of the complete antigens simply. During the reaction, amino group on the protein can also be linked with the carboxyl group on itself. To reduce the self-coupling, we added excess ethylenediamine (EDA) first to block the proteins and it could be seen that the characters of the modified proteins did not change from its UV spectrum. Now no relative reports about modified protein could be obtained in China. Also it was found that coupling effects could be obviously improved after the carrier proteins were treated with EDA. But to various carrier proteins, the coupling effects were greatly influenced by different coupling methods. It was better to use active ester method than carbodiimide method when carrier protein was OVA. But when BSA was used as carrier protein, the coupling effects of the carbodiimide method were better.

Preparation and Evaluation of an Enrofloxacin Self-Micro Emulsion for Veterinary Use

Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate.

Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion

Double-coated Enrofloxacin Microparticles with Chitosan and Alginate: Preparation, Characterization and Taste-Masking Effect Study.

Pharmacokinetics, Withdrawal Time, and Dietary Risk Assessment of Enrofloxacin and Its Metabolite Ciprofloxacin, and Sulfachloropyridazine‐trimethoprim in Taihe Black‐boned Silky Fowls

Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia Coli in Broilers.

Clinical Efficacy and Residue Depletion of 10% Enrofloxacin Enteric-Coated Granules in Pigs

Pharmacokinetics and lung-targeting characterization of a newly formulated enrofloxacin preparation

Pharmacokinetics Studies of Enrofloxacin Injectable Insitu Forming Gel Indogs

Pharmacokinetic Studies of an in Situ Forming Gel System for Controlled Delivery of Enrofloxacin in Pigs

Pharmacokinetics and Pharmacodynamics of Enrofloxacin Treatment of Escherichia Coli in a Murine Thigh Infection Modeling.

Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig.

Preparation of Immunogens for Antibody Production Against Enrofloxacin and the Optimization of Conjugation Conditions

Pharmacokinetic and Pharmacodynamic Integration and Modeling of Enrofloxacin in Swine for Escherichia coli.

The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium

In Vitro and in Vivo Antibacterial Activities of Tosufloxacin Nanoemulsion

Preparation for Lung Targeting Microspheres of Enrofloxacin

Studies on synthesis and characteristics of complete antigens of Enrofloxacin

Determination of Median Lethal Dose of Enrofloxacin Microemulsion in Mice

Toxicologic Effect and Transcriptome Analysis for Short-Term Orally Dosed Enrofloxacin Combined with Two Veterinary Antimicrobials on Rat Liver.

Solid Lipid Nanoparticles with Enteric Coating for Improving Stability, Palatability, and Oral Bioavailability of Enrofloxacin